Chemotherapy-induced Peripheral Neuropathy in Patients with Breast Cancer: Associated Factors and Impact on Health-Related Quality of Life
- Author:
Yu Hyeon CHOE
1
;
Soo Hyun KIM
;
Hyun Soo OH
;
Wha Sook SEO
;
Sun Hee LEE
Author Information
- Publication Type:Original Articles
- From:Asian Oncology Nursing 2020;20(2):83-91
- CountryRepublic of Korea
- Language:0
-
Abstract:
Purpose:This study aimed to identify factors associated with the occurrence of chemotherapy-induced peripheral neuropathy (CIPN) and to study its impact on health-related quality of life (HRQoL) in patients with breast cancer.
Methods:In total, 137 women with breast cancer who had undergone more than one cycle of chemotherapy were recruited for this descriptive study from the outpatient department of a university hospital in Incheon, Korea. Data were collected using a self-reported questionnaire, which included the European Organization for Research and Treatment of Cancer (EORTC) QLQ-CIPN20 and EORTC QLQ-C30.
Results:The mean CIPN score between patients was 13.57 on the sensory scale, 15.87 on the motor scale, and 25.06 on the autonomic scale. Of the studied socio-demographic, disease and treatment, and health behavior-related factors, only the chemotherapy regimen was significantly associated with CIPN (t = 2.50, p= .013). Taxane-based chemotherapy was significantly related to higher CIPN scores. Regression analyses revealed that CIPN was a factor that was significantly influential on HRQoL, adjusting for socio-demographic and clinical factors.
Conclusion:This study suggests that oncology nurses need to be aware of the increased risk of CIPN in patients with breast cancer undergoing taxane-based chemotherapy. In addition, interventions for alleviating CIPN may be required to improve HRQoL among these patients.
